- Home
- NAMS vs SUPN Comparison
NAMS vs SUPN Comparison
Compare NAMS & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAMS
- SUPN
- Stock Information
- Founded
- NAMS 2019
- SUPN 2005
- Country
- NAMS Netherlands
- SUPN United States
- Employees
- NAMS N/A
- SUPN N/A
- Industry
- NAMS Biotechnology: Pharmaceutical Preparations
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- NAMS Health Care
- SUPN Health Care
- Exchange
- NAMS Nasdaq
- SUPN Nasdaq
- Market Cap
- NAMS 3.1B
- SUPN 2.6B
- IPO Year
- NAMS N/A
- SUPN 2012
- Fundamental
- Price
- NAMS $35.94
- SUPN $55.53
- Analyst Decision
- NAMS Strong Buy
- SUPN Strong Buy
- Analyst Count
- NAMS 10
- SUPN 4
- Target Price
- NAMS $43.70
- SUPN $63.25
- AVG Volume (30 Days)
- NAMS 1.3M
- SUPN 734.5K
- Earning Date
- NAMS 11-06-2025
- SUPN 11-04-2025
- Dividend Yield
- NAMS N/A
- SUPN N/A
- EPS Growth
- NAMS N/A
- SUPN 1411.53
- EPS
- NAMS N/A
- SUPN 1.14
- Revenue
- NAMS $64,006,000.00
- SUPN $665,125,000.00
- Revenue This Year
- NAMS N/A
- SUPN $7.31
- Revenue Next Year
- NAMS N/A
- SUPN $21.87
- P/E Ratio
- NAMS N/A
- SUPN $48.67
- Revenue Growth
- NAMS 762.15
- SUPN 5.55
- 52 Week Low
- NAMS $14.06
- SUPN $29.16
- 52 Week High
- NAMS $41.47
- SUPN $55.90
- Technical
- Relative Strength Index (RSI)
- NAMS 59.08
- SUPN 79.75
- Support Level
- NAMS $35.50
- SUPN $51.84
- Resistance Level
- NAMS $36.81
- SUPN $54.79
- Average True Range (ATR)
- NAMS 2.26
- SUPN 1.51
- MACD
- NAMS -0.42
- SUPN 0.40
- Stochastic Oscillator
- NAMS 22.49
- SUPN 94.26
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.